Sacral Neuromodulation in Urological Practice - 19/04/17
Abstract |
Sacral neuromodulation (SNM) is a minimally invasive, restorative treatment to improve voiding and elimination functions. We give a historical perspective of SNM and explore the evidence for the use of this therapy for Food and Drug Administration-approved pathologies as well as disease processes that are being treated internationally. Ensuring optimal lead placement increases the potential of a comfortable, durable, and efficacious response. The future of SNM aims to maximize its potential benefit, refine its use, and minimize its risks and cost. Evolution of the therapy includes better device options, better software for patient and clinician use, more programming capabilities, and new nerve targets.
Le texte complet de cet article est disponible en PDF.Plan
| Financial Disclosure:Michael J. Ehlert is a paid consultant for Nuvectra. Steven W. Siegel is a paid consultant for Medtronic, Allergen, and NuVectra; has sponsored research from Medtronic, Allergen, and IPSEN; and is a proctor and speaker for Medtronic. The remaining author declares that he has no relevant financial interests. |
Vol 99
P. 14-22 - janvier 2017 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?

